KYAN-001 / KYAN Therap - LARVOL DELTA

KYAN Therapeutics Presents Preclinical Data on Novel HDACi Targeting KRAS-mutated Cancers at AACR-KCA Conference (EIN Presswire) - "The study highlighted the identification of effective combination therapies with KYAN-001, a first-in-class histone deacetylase (HDAC) 4/6 inhibitor, against prostate and pancreatic cell lines and patient-derived organoids, including KRAS-mutant lines...he study demonstrated the synergism between HDAC and MEK inhibition on solid tumors. Additionally, the combinations found were unique for each cell line with different subtypes of KRAS mutation, underscoring the utility of Optim.AI in precision medicine and drug prioritization for the same class of drugs."

Preclinical • Gastrointestinal Cancer • Genito-urinary Cancer • Oncology • Pancreatic Cancer • Prostate Cancer • Solid Tumor